analytics_image
\
Vantage Market Research
Vantage Market Research

Reports - Obesity Treatment Market

iconHealthcare

Obesity Treatment Market

Obesity Treatment Market Size | Industry Report, 2035 by Surgery (Adjusting gastric Banding, Roux-en-Y Gastric Bypass, Sleeve gastrectomy, Biliopancreatic diversion with Duodenal Switch), by Drugs (Appetite suppressants, Combination drugs, Malabsorption, Satiety drugs), by Region (North America, Europe, Asia Pacific, Latin America

ppt icon
pdf icon
xlsx icon
power bi icon
immediate delivery icon

Industry Leaders Trust Us For Actionable Intelligence

Revenue Insights

Market Size in 2024

USD 22.2 Billion

Market Size By 2035

USD 194.1 Billion

CAGR (2025 - 2035)

21.80%

Largest Region

North America

Fastest Region

Asia Pacific

Base Year

2024

Historic Data

2021 - 2023

Forecast Period

2025 - 2035

Segments Covered

By Surgery, By Drugs, By Region

Report Coverage

The final deliverable will encompass both quantitative and qualitative data, providing a comprehensive analysis of the market. The scope is customizable.

Overview

Market Synopsis:

Obesity Treatment Market Size, 2024 To 2035 (USD Billion)

The global Obesity Treatment Market is valued at USD 22.2 Billion in 2024 and is projected to reach a value of USD 194.1 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 21.80% between 2025 and 2035. Obesity is a huge problem in affluent countries as well as low- and middle-income ones. Overweight and obesity, according to a World Health Organization fact sheet, are linked to a variety of diseases and lead to a greater mortality rate than malnutrition. Chronic disorders such as hypertension, diabetes, and orthopedic diseases are common in the overweight and obese population.

The COVID-19 pandemic has wreaked havoc on the global population and economy. Across the globe, the COVID-19 pandemic caused substantial obstacles to the health-care system. Due to the imposition of lockdown, which resulted in trade restrictions and supply chain disruptions, it had a negative impact on the growth of the Obesity Treatment market for a short period of time. In addition, many non-essential medical and surgical treatments were halted, which had an impact on market growth.


Rise in Healthcare Expenditure

According to the World Health Organization, a sedentary lifestyle is a primary contributor to obesity, sickness, and disability. Obesity is responsible for over 2.0 million deaths per year. In addition, weight increase in teens is caused by a shift in preference toward sedentary lifestyles, physical inactivity, and altering eating habits. The rise in single-person homes, nuclear families, and families with working parents is encouraging people to embrace unhealthy lifestyles, which is driving up demand for fast-food meals. People are turning to ready-to-eat food as their schedules get increasingly hectic and their stress levels rise. Furthermore, the young have a proclivity for overeating and inadequate nutritional intake, both of which have negative health consequences. Physical inactivity, excessive video game playing, and lengthy hours of television viewing are all contributing to an increase in the number of obese teenagers and overweight adults over the age of 18.


High Cost Involved in the Research and Development

The high cost of obesity drug research and development, along with limited financial assistance, pose a significant impediment to the obesity management markets growth. Furthermore, longer research and development efforts, as well as the inclusion of clinical trials to evaluate pharmaceuticals, raise overall costs. As a result, given the current situation, producers must exercise caution and ensure that they invest in markets that deliver a higher return on investment. The risks and constraints posed by obesity medications' high development costs could stifle worldwide market expansion. Due to the high cost of surgical procedures such as gastric sleeve surgery, gastric bypass, adjustable gastric banding, and intragastric balloon treatment, non-invasive fat reduction technologies are becoming more popular.

The Obesity Treatment market scope can be tabulated as below:



Market Segmentation:

The Global Obesity Treatment Market has been segmented by Surgery into Adjusting gastric Banding, Roux-en-Y Gastric Bypass, Sleeve gastrectomy, Biliopancreatic diversion with Duodenal Switch and Endoscopic Procedures. By Drugs, into Appetite suppressants, Combination drugs, Malabsorption and Satiety drugs.Based on Region, the Obesity Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.


North America to Continue Dominating the Obesity Treatment Market

With a revenue share of roughly 52 percent in 2024, North America dominated the global sector. The regions domination was mostly attributable to the regions expanding overweight and obese population, as well as rising rates of hypertension and diabetes. Furthermore, the shift toward less invasive techniques is expected to aid the growth of the obesity treatment market in North America. The regional market growth can be attributed to expanding geriatric populace, increasing surgical procedures, expanding and presence of established healthcare infrastructure. One of the primary causes leading to the growing demand for Obesity Treatment techniques and technologies among academic and research organisations, as well as healthcare firms in North America, is increased R&D spending.

Key Players:

Key participants operating in the Obesity Treatment market are: VIVUS Inc. (US)

The Obesity Treatment market is segmented as follows:

Market Segmentation

ParameterDetails
Segment Covered

By Surgery

  • Adjusting gastric Banding (27.1%)
  • Roux-en-Y Gastric Bypass
  • Sleeve gastrectomy
  • Biliopancreatic diversion with Duodenal Switch
  • Endoscopic Procedures

By Drugs

  • Appetite suppressants
  • Combination drugs
  • Malabsorption (5.6%)
  • Satiety drugs

By Region

  • North America (U.S., Canada, Mexico) (51.1%)
  • Europe (Germany, France, U.K., Italy, Spain, Nordic Countries, Benelux Union, Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, South-East Asia, Rest of Asia Pacific)
  • Latin America (Brazil, Argentina, Rest of Latin America)
  • Middle East & Africa
Companies Covered
  • VIVUS Inc. (US)
  • Arena Pharmaceuticals Inc. (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Novo Nordisk A/S (Denmark)
  • Allergan Plc (US)
  • Medtronic (US)
  • Ethicon (a subsidiary of Johnson & Johnson) (US)
  • Cousin Biotech (France)
  • EnteroMedics Inc. (US)
  • and USGI Medical Inc. (US).
Customization ScopeEnjoy complimentary report customization—equivalent to up to 8 analyst working days—with your purchase. Customizations may include additions or modifications to country, regional, or segment-level data.
Pricing and purchase optionsAccess flexible purchase options tailored to your specific research requirements. Explore purchase options

Report coverage & Deliverables

Our PDF Reports And Online Dashboard
Will Help You Stay Ahead In The Market.

    Key features include:

  • Check
    Competitive benchmarking
  • Check
    Historical data and future forecasts
  • Check
    Company-wise revenue breakdown
  • Check
    Regional growth opportunities
  • Check
    Latest market trends and dynamics
  • Check
    Impact of emerging technologies like AI and automation
  • Check
    Key regulatory updates and ESG considerations

FAQ‘s

Related Reports

vantage logo

Vantage Market Research & Consultancy Services is all about providing accurate and reliable market intelligence to its clients for the seamless execution of their business growth strategies.

© 2025 Vantage Market Research. All right reserved
Secured Bysecured by
Obesity Treatment Market Size | Industry Report, 2035